International Journal of Clinical Pharmacy

, Volume 38, Issue 1, pp 25–29 | Cite as

Medicine information leaflets for non-steroidal anti-inflammatory drugs in Thailand

  • Pacharaporn Phueanpinit
  • Juraporn Pongwecharak
  • Janet Krska
  • Narumol JarernsiripornkulEmail author
Short Research Report


Background The importance of promoting the use of patient-oriented medicines leaflets is recognized in many countries. Leaflets should include basic information plus specific warnings, and be provided with all medicines, but there is little attempt at enforcement of these requirements in Thailand. Objective To determine content and availability of Thai information leaflets for nonsteroidal anti-inflammatory drugs (NSAIDs). Methods Leaflets for all NSAIDs available for purchase from 34 pharmacies in a large city were evaluated against a checklist and number of leaflets assessed against number of medicine packs available in each pharmacy. Results Of the 76 leaflets for ten different NSAIDs, 67 (88 %) were for locally manufactured products. Only 22 % of 76 leaflets were sufficient in number for distribution with medicines, while only 4 % had patient-oriented leaflets. No leaflet covered all topics in the checklist. Less than half included safety information, such as contraindications (46 %), precautions (47 %), and adverse drug reactions (34 %). Locally-produced leaflets provided less information than those for originator products and no leaflet included all the warnings required by Thai regulations. Conclusion This study illustrates the variable availability and quality of NSAID information leaflets. The lack of accessible essential information about medicines in Thailand requires urgent attention to enable patients to minimise adverse reactions.


Information leaflets Non-steroidal anti-inflammatory drugs Drug safety information Thailand 



The authors would like to thank all community pharmacists who supplied the information leaflets in this study.


This work received financial support from Khon Kaen University Integrated Multidisciplinary Research Cluster [Grant No. MIH-2554-Ph.D-07] and the Graduate School of Khon Kaen University [Grant No. 55222103].

Conflicts of interest

The authors declare no conflict of interest.


  1. 1.
    Aslani P, Benrimoj SI, Krass I. Development and evaluation of a training program to foster the use of written drug information in community pharmacies. Part 2: evaluation. Pharm Educ. 2007;7:141–9.CrossRefGoogle Scholar
  2. 2.
    Raynor DK, Blenkinsopp A, Knapp P, Grime J, Nicolson DJ, Pollock K, et al. A systematic review of quantitative and qualitative research on the role and effectiveness of written information available to patients about individual medicines. Health Technol Assess. 2007;11(5):1–160.CrossRefGoogle Scholar
  3. 3.
    Shrank WH, Avorn J. Educating patients about their medications: the potential and limitations of written drug information. Health Aff. 2007;26:731–40.CrossRefGoogle Scholar
  4. 4.
    Kesselheim AS, Franklin JM, Avorn J, Duke JD. Speaking the same language? International variations in the safety information accompanying top-selling prescription drugs. BMJ QualSaf. 2013;22:727–34.CrossRefGoogle Scholar
  5. 5.
    Sawalha AF, Sweileh WM, Zyoud SH, Jabi SW. Comparative analysis of patient package inserts of local and imported anti-infective agents in Palestine. Libyan J Med. 2008;3:181–5.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Al-ageed SA. Evaluation of medication package inserts in Saudi Arabia. Drug Healthc Patient Saf. 2012;4:33–8.Google Scholar
  7. 7.
    Svarstad BL, Bultman DC, Mount JK, Tabak ER. Evaluation of written prescription information provided in community pharmacies: a study in eight states. J Am Pharm Assoc. 2003;43:383–93.CrossRefGoogle Scholar
  8. 8.
    Svarstad BL, Mount JK, Tabak ER. Expert and consumer evaluation of patient medication leaflets provided in U.S. pharmacies. J Am Pharm Assoc. 2005;45:443–51.CrossRefGoogle Scholar
  9. 9.
    Thai Food and Drug Administration. Developmental testing of providing information of patient information leaflets. Bangkok, 2012.Google Scholar
  10. 10.
    Health Product Vigilance Center. Adverse drug reactions reporting 2011. Bangkok: Thai Food and Drug Administration, Ministry of Public Health, 2011.Google Scholar
  11. 11.
    Schjerning Olsen AM, Gislason GH, McGettigan P, Fosbøl E, Sørensen R, Hansen ML, et al. Association of NSAID use with risk of bleeding and cardiovascular events in patients receiving antithrombotic therapy after myocardial infarction. JAMA. 2015;313:805–14.CrossRefPubMedGoogle Scholar
  12. 12.
    Raynor DK, Knapp P, Silcock J, Parkinson B, Feeney K. “User-testing” as a method for testing the fitness-for-purpose of written medicine information. Patient EducCouns. 2011;83:404–10.CrossRefGoogle Scholar
  13. 13.
    Phueanpinit P, Jarernsiripornkul N, Pongwecharak J, Krska J. Hospital pharmacists’ roles and attitudes in providing information on the safety of non-steroidal anti-inflammatory drugs in Thailand. Int J Clin Pharm. 2014;36:1205–12.CrossRefPubMedGoogle Scholar

Copyright information

© Koninklijke Nederlandse Maatschappij ter bevordering der Pharmacie 2015

Authors and Affiliations

  • Pacharaporn Phueanpinit
    • 1
  • Juraporn Pongwecharak
    • 2
  • Janet Krska
    • 3
  • Narumol Jarernsiripornkul
    • 1
    Email author
  1. 1.Department of Clinical Pharmacy, Faculty of Pharmaceutical SciencesKhon Kaen UniversityKhon KaenThailand
  2. 2.Faculty of Pharmacy, Rangsit CenterThammasat UniversityPathumthaniThailand
  3. 3.Medway School of PharmacyUniversities of Greenwich and KentKentUK

Personalised recommendations